Heterocyclic Compounds with 4 or More Rings
-
Subject Areas on Research
-
Acute Hemodynamic Effects and Tolerability of Phosphodiesterase-1 Inhibition With ITI-214 in Human Systolic Heart Failure.
-
Anthrabenzoxocinones from Streptomyces sp. as liver X receptor ligands and antibacterial agents.
-
Autophagy inhibitor Vacuolin-1 interferes with lipid-based small interference RNA delivery.
-
Blebbistatin, a novel inhibitor of myosin II ATPase activity, increases aqueous humor outflow facility in perfused enucleated porcine eyes.
-
Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations.
-
Dupuytren's fibroblast contractility by sphingosine-1-phosphate is mediated through non-muscle myosin II.
-
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
-
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
-
Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines.
-
NOTUM is a potential pharmacodynamic biomarker of Wnt pathway inhibition.
-
Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation.
-
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.
-
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
-
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
-
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
-
Role of SIRT1 and Progesterone Resistance in Normal and Abnormal Endometrium.
-
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
-
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
-
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.
-
Sparstolonin B (SsnB) attenuates liver fibrosis via a parallel conjugate pathway involving P53-P21 axis, TGF-beta signaling and focal adhesion that is TLR4 dependent.
-
Sparstolonin B attenuates early liver inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via NADPH oxidase activation.
-
Synthesis of the tetracyclic framework of the erythrina alkaloids using a [4 + 2]-cycloaddition/Rh(I)-catalyzed cascade of 2-imidofurans.
-
Targeting RET Kinase in Neuroendocrine Prostate Cancer.
-
The Functional Landscape of Patient-Derived RNF43 Mutations Predicts Sensitivity to Wnt Inhibition.
-
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
-
Widespread Repression of Gene Expression in Cancer by a Wnt/β-Catenin/MAPK Pathway.
-
Wnt addiction of genetically defined cancers reversed by PORCN inhibition.
-
Keywords of People